#APHEXDA
What happens to your Aphexda royalty obligations if Aphexda underperforms in a given quarter? A hard budget discipline beats a hot pipeline every time.
November 18, 2026 at 1:19 PM
BioLineRx enters into $5.6mm royalty monetization transaction w/ Soleus Capital
*Sale of future Aphexda royalties
#$BLRX retains rights to future commercial milestone payments
*Proceeds will support GLIX1 development & partial loan repayment to Blackrock
*30Nov close
finance.yahoo.com/healthcare/a...
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into an agree...
finance.yahoo.com
November 18, 2026 at 1:10 PM
BioLineRx Secures $5.6 Million Funding through Royalty Monetization Deal#Israel#Tel_Aviv#BioLineRx#APHEXDA#Soleus_Capital
BioLineRx Secures $5.6 Million Funding through Royalty Monetization Deal
BioLineRx Ltd. has finalized a $5.6 million royalty monetization agreement with Soleus Capital to augment its funding for oncological research and drug development.
third-news.com
November 18, 2026 at 12:16 PM
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
BioLineRx (BLRX) signed an agreement with Soleus Capital Management and its affiliates to sell future APHEXDA royalties for a one-time $5.6 million payment. Soleus will acquire BioLineRx’s 14.4% royalty interest in future APHEXDA net sales under its license with Ayrmid Pharma. BioLineRx retains rights to potential commercial milestone payments and royalties attributable to periods before closing. The deal is expected to close on or about November 30, 2026.BioLineRx plans to use the non-dilutive proceeds to support research and development, including GLIX1, and to make a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with that repayment, BioLineRx’s current $4 million minimum cash balance requirement will be eliminated. The GLIX1 Phase 1/2a trial is enrolling the fourth of five planned dosing cohorts.
www.stocktitan.net
November 18, 2026 at 12:00 PM
BioLineRx reports 2Q
*Call @ 8:30 am ET
*GLIX1 in GBM Ph1/2a ongoing
*Aphexda royalty revenue of $0.3mm
#$BLRX
ir.biolinerx.com/news-release...
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | BioLineRx
The Investor Relations website contains information about BioLineRx's business for stockholders, potential investors, and financial analysts.
ir.biolinerx.com
August 31, 2026 at 11:57 AM
BioLineRx Closes $3.75 Million Direct Offering for Future Oncology Breakthroughs#BioLineRx#APHEXDA#GLIX1
BioLineRx Closes $3.75 Million Direct Offering for Future Oncology Breakthroughs
BioLineRx has secured $3.75 million through a registered direct offering and concurrent private placement aimed at advancing its oncological therapies.
third-news.com
August 28, 2026 at 12:04 PM
BioLineRx to report 2Q on 31Aug
*call @ 8:30 am ET
#$BLRX
We'll be looking for Aphexda sales trends, GLIX1 updates & status of global partnerships including the Ph2b PDAC trial with Columbia University
finance.yahoo.com/healthcare/a...
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudite...
finance.yahoo.com
August 25, 2026 at 12:23 PM
BioLineRx reported 1Q25
*new asset search continues
*Aphexda generated $0.3mm license revenue
*31May ASCO PDAC presentation
$BLRX
ir.biolinerx.com/news-release...
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update | BioLineRx
The Investor Relations website contains information about BioLineRx's business for stockholders, potential investors, and financial analysts.
ir.biolinerx.com
May 27, 2025 at 11:23 AM
#BioLineRx ( #BLRX) shines in Q1 2025! Advancing APHEXDA® for stem cell mobilization and expanding oncology pipeline with promising trials. Strong financials with $40.2M in cash fuel growth. Exciting times for biotech innovation!

prismmarketview.com/biolinerx-hi...
May 27, 2025 at 5:37 PM
#BLRX: Aphexda Transition Progressing buff.ly/4hHQ4qv
February 19, 2025 at 2:18 PM
BioLineRx Delivers Promising Progress in Q1 2025 Financial Results and Corporate Developments#Israel#Tel_Aviv#BioLineRx#APHEXDA#motixafortide
BioLineRx Delivers Promising Progress in Q1 2025 Financial Results and Corporate Developments
BioLineRx has reported its Q1 2025 financial results, showcasing significant advancements in drug development and corporate strategies in oncology and rare diseases.
third-news.com
May 27, 2025 at 11:16 AM
BioLineRx Announces Strong Financial Results for 2024 and Strategic Corporate Developments#Israel#Tel_Aviv#oncology#BioLineRx#APHEXDA
BioLineRx Announces Strong Financial Results for 2024 and Strategic Corporate Developments
BioLineRx Ltd. reported impressive 2024 financial results highlighting strategic partnerships and enhanced focus on oncology and rare diseases.
third-news.com
April 2, 2025 at 2:33 AM
BioLineRx Shares Strategic Outlook Amidst Bolder Future Goals#Israel#Tel_Aviv#oncology#BioLineRx#APHEXDA
BioLineRx Shares Strategic Outlook Amidst Bolder Future Goals
BioLineRx provides an in-depth letter to shareholders detailing its future strategies and financial outlook following a significant licensing agreement.
third-news.com
January 21, 2025 at 12:28 PM
BioLineRx Announces Positive Developments in Financials and Strategic Directions for 2024#healthcare#Israel#Tel_Aviv#BioLineRx#APHEXDA
BioLineRx Announces Positive Developments in Financials and Strategic Directions for 2024
BioLineRx shares insights into its third-quarter financial results and strategic initiatives aimed at enhancing shareholder value for 2024.
third-news.com
November 25, 2024 at 12:13 PM
#BLRX BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

https://www.stocktitan.net/news/BLRX/bio-line-rx-and-ayrmid-ltd-enter-into-exclusive-license-agreement-to-zu9edtosljhn.html
November 21, 2024 at 11:30 AM